Markets:

Overview

News

Currencies

International

Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

18.94 +0.42 (+2.27%)

Delayed Quote Updated: 11:46 AM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

20 21 Next >

As Health Problems Mount Patients Welcome New Treatments

June 14, 2022

Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,...

Via FinancialNewsMedia

Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial

June 09, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Moderna Pops On Updated Booster Data, But Analyst Says It Needs A 'Second Act' ↗

June 08, 2022

Moderna tested a bivalent booster, which targets two Covid strains in one shot.

Via Investor's Business Daily

Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22 ↗

May 11, 2022

Via Benzinga

Quant Ratings Updated on 66 Stocks ↗

June 06, 2022

Out of the 66 stocks that were upgraded/downgraded this weekend, 12 were downgraded to a D-rating. And I'm giving you the first 10.

Via InvestorPlace

Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA

May 31, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna

May 31, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna

May 31, 2022

Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1,...

From Moderna, Inc.

Via AccessWire

Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma

May 26, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Current Report: Takeda Pharmaceutical ↗

May 18, 2022

Takeda’s price per share was $14.31 as of yesterday's market close. One year ago its price was $17.20.

Via Talk Markets

Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022

May 11, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories

April 26, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients ↗

April 22, 2022

Via Benzinga

Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay

April 22, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Novavax Stock Looks Like a Good Value With Its New Combined Vaccine ↗

April 21, 2022

NVAX stock could be worth 63% more based on its new combination flu and Covid-19 vaccine after passing Phase 1/2 clinical trials.

Via InvestorPlace

Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan

April 18, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report ↗

April 18, 2022

Via Benzinga

Takeda’s TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States

April 18, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference ↗

April 13, 2022

Via Benzinga

Cognitive Drugs Market Expected Reach Revenues Of $21 Billion in 2027

April 13, 2022

Palm Beach, FL – April 13, 2022 – FinancialNewsMedia.com News Commentary – Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent...

Via FinancialNewsMedia

Takeda Announces Completion of Acquisition of Own Shares

April 13, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More ↗

April 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Takeda’s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)

April 12, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners

April 05, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Monday Markets News ↗

March 28, 2022

Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved.

Via Talk Markets

Takeda’s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)

March 28, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection ↗

March 08, 2022

Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID...

Via Benzinga

Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients

February 28, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Roche And AstraZeneca Settle Ultomiris Patent Lawsuit ↗

February 22, 2022

Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly...

Via Benzinga

Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics ↗

February 22, 2022

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four...

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.